3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

6 Customer Reviews

  • granulosa cells (GCs) with 24 h of melatonin (10 μM) treatment were rinsed in PBS, and then exposed to H2O2 (200 μM) for 2 h. The autophagy inhibitor 3-MA (10 mM), or the apoptosis inhibitor Z-VAD-FMK (50 μM) were added 1 h prior to H2O2 incubation. Cell viability was determined using the CCK-8 assay. Data represent mean ± S.E; n = 3 in each group. *P < 0.05 (**P < 0.01) vs. vehicle group at 0 h. # Represents P < 0.05 (## Represents P < 0.01) vs. H2O2-only-treated cells. & Represents P > 0.05 vs. H2O2-only-treated cells. N, not significant, P > 0.05. δ Represents P < 0.05 (δδ Represents P < 0.01) vs. Z-VAD-FMK-treated cells.

    Redox Biol, 2018, 18:138-157. 3-Methyladenine (3-MA) purchased from Selleck.

    MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

  • Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

    PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

  • After getting treated with 10 μM compound C for indicated time periods with or without 50 μM 3-MA (C) pre-treatment for 1 h, the levels of indicated proteins in QBC939 and RBE cells were analyzed using Western blot.

    J Cell Biochem, 2017, 119(7):5538-5550. 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NHW5WWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSzcW0> NIWyZWUzcA>? NFzNb4lFVVOR MU\y[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E MUeyOVcyPjV4MR?=
A549  NGXDfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyzcW0> M322dVJp MXLEUXNQ NGrUOlhz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F M3T4UVI2PzF4NU[x
95D NWP2UpVKSXCxcITvd4l{KEG|c3H5 Mk\NOY1O MWWybC=> NIHzZZRFVVOR M2DiSolvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= NGXTXJQzPTdzNkW2NS=>
A549  MYPBdI9xfG:|aYOgRZN{[Xl? MnO4OY1O NEL0b|AzcA>? MUfEUXNQ MUjpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? NGrGco0zPTdzNkW2NS=>
NBL-W-S  NY\kc2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxcW0> Mk\NOog> NE\URlFmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5 NGXGeWIzPTN{M{KyNi=>
NBL-W-S  NGLte|NCeG:ydH;zbZMhSXO|YYm= MWmxcW0> Ml;kOog> NFTsR41qdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x MV[yOVMzOzJ{Mh?=
A2780cp  M2jUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ruVFFuVQ>? Mn3INYg> Mn7LbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NETXcGwzPTN{Mk[5OC=>
A549  M3zpTmZ2dmO2aX;uJGF{e2G7 M1y4c|VuVQ>? MkjzNog> NIn4OlB{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> M3zScFI2Ojh3NkK4
H157 MXjGeY5kfGmxbjDBd5NigQ>? M1;jZlVuVQ>? NV\MPXNLOmh? M2[0fZN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NWP1U|F7OjV{OEW2Nlg>
MDR MYfBdI9xfG:|aYOgRZN{[Xl? M{fOflExdU1? NYnERW43Pmh? MoHVd5Rz\W6pdHjlcpMhfGinIIDve4VzKG:oIHHueIlk[W6lZYKg[JJ2\3N? NVvrRXNHOjVyMUm3NFE>
HT-29  NWfiNXpLSXCxcITvd4l{KEG|c3H5 NXTONHJZOW2P NIr1dlc1QGh? NVHuU|hKTE2VTx?= NIL5b2hmdmijbnPld{Bjd3K2ZYrvcYljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MVGyOFg1OjF3OB?=
Microglia  M3zrSmFxd3C2b4Ppd{BCe3OjeR?= M4DrdlVuVQ>? MWiyOIg> MWLk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= MVWyOFgyQDZyMR?=
A2780cp NFvUNVVCeG:ydH;zbZMhSXO|YYm= M1vGdlIvPW2P NITSR5kycA>? MX3k[GgzVw>? M3\JfoVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NUj6eVd[OjR6MUe5OFY>
HepG2 M4X6U2Z2dmO2aX;uJGF{e2G7 M135W|VuVQ>? NFzGUI41cA>? MUnpcoNz\WG|ZYOgTGwhemWuZXHz[S=> NWK5[4xuOjR5MUO1PFc>
A549 NVXCSXF2SXCxcITvd4l{KEG|c3H5 MYO1cW0> NF7GTZI1QGh? MVvk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK MoPINlQ4ODZ|MEO=
U2OS NYi4[m12SXCxcITvd4l{KEG|c3H5 MnTnNVBuVQ>? NX\yendFOjSq MXnpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> Mn3RNlQ3OzlyMUO=
Saos-2 NIDxOlRCeG:ydH;zbZMhSXO|YYm= NGfuT|QyOG2P Mlr5NlRp NGSzO3dqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? MXmyOFY{QTBzMx?=
A549 MoL1RZBweHSxc3nzJGF{e2G7 M3juRlExdU1? NYfL[3ppPDiq M3LX[4Fk[2WuZYLheIV{KHSqZTDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBRXFh? MXmyOFYzPjd{Mh?=
HCT116  MWnBdI9xfG:|aYOgRZN{[Xl? NEnJbXo2dU1? NFixZoIzPGh? M2rPWYVvcGGwY3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDhdIlo\W6rbh?= M1mxdlI1PjJ4NUKy
HGC-27 MXrGeY5kfGmxbjDBd5NigQ>? M3X0bFExdU1? NIf5XVIycA>? NIjxRmlqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhdG:|czDifUBTSURyMEGgc5IhVUtvMkKwOi=> NHrlZoszPDRzNkO0PS=>
U2OS  M{nmWWZ2dmO2aX;uJGF{e2G7 Mmi5NE42NzGvTR?= MorCOFhp NWfE[mN1cW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MVGyOFM2QDN2Mh?=
MG-63 NEfQbHJHfW6ldHnvckBCe3OjeR?= NHTIU2IxNjVxMX3N MkjmOFhp NYG4eVZOcW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MX[yOFM2QDN2Mh?=
MG-63 NEjQUYFCeG:ydH;zbZMhSXO|YYm= NVfQXm5bOC53L{HtUS=> MoHsN|Jp MYXlcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| M1vUOFI1OzV6M{Sy
MG-63 NIPoZ25CeG:ydH;zbZMhSXO|YYm= M{DMSlExdU1? MUKxNog> Mlva[Y5p[W6lZYOgSHAucW6mdXPl[EBieG:ydH;zbZM> NEe5d4czPDN3OEOwNS=>
NTUB1 NFT1NlNCeG:ydH;zbZMhSXO|YYm= MUO1cW0> MmXvNU42cA>? MnfmdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ M37KWlI1OzR7MUe2
T24 NXrrS2ZZSXCxcITvd4l{KEG|c3H5 NVzqdGtFPW2P MnL0NU42cA>? NVHYR3E6eG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| NVjF[5lMOjR|NEmxO|Y>
SGC-7901  NYL5eYpQSXCxcITvd4l{KEG|c3H5 NXTKd45mOm2P NITE[I8ycA>? NYTSPI4ycW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= MUmyOFMzOTN2MB?=
SMMC-7721 NIrHW4pCeG:ydH;zbZMhSXO|YYm= NVn3VYhoOm2P NH71T2wycA>? NWrWZ5ZkcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NIPHXlgzPDN{MUO0NC=>
ECSCs  MV;BdI9xfG:|aYOgRZN{[Xl? MUexNI1O NU\SbmR7PGh? NH7WXWFl\WO{ZXHz[ZMhemGyYX35Z4lvNXS{ZXH0[YQh[XCxcITvd4l{ M3fESVI1OzF7MUC5
MCF-7  M{D3OGZ2dmO2aX;uJGF{e2G7 NU[1e3RrOTCvTR?= MnLhNlRp M3HheolvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= NVn6fo43OjR|MUW1O|g>
UOK257 MVLBdI9xfG:|aYOgRZN{[Xl? MnjUOY1O MonlN4g> NH3kfWpmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li NV3CboNjOjR|MEW2NFQ>
ACHN-5968 Mlq0RZBweHSxc3nzJGF{e2G7 NHm0bos2dU1? NEe1eVM{cA>? NVGxNJZ3\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= NH;tR4MzPDNyNU[wOC=>
Huh7 NIWwfGlCeG:ydH;zbZMhSXO|YYm= Mn\GNo1O NGPNNnIyOmh? MVHEUXNQ M17CbIlvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo NWXSdJp6OjR{OUezNFA>
Hep3B M1nQNmFxd3C2b4Ppd{BCe3OjeR?= NID6e2kzdU1? MYGxNog> MoD1SG1UVw>? MoXFbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= NVH5eIdLOjR{OUezNFA>
RKO MVjGeY5kfGmxbjDBd5NigQ>? M{fRW|JuVQ>? NY\VRYsyOWh? MY\EUXNQ NFjrfXhmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MnPSNlQzQTF5N{e=
HepG2 E47 MnXxSpVv[3Srb36gRZN{[Xl? MnfNNk42dU1? NFzQRWs1QGh? NWXEc3EycW6lcnXhd4V{KHSqZTD0c5hq[2m2eTDv[kBCSSxiQmPPMEBidmRiQ1PsOC=> NYnOUZc1OjR{N{O3N|g>
LoVo  MlzLRZBweHSxc3nzJGF{e2G7 MU[1cW0> MVe0PIg> M2mwZoVvcGGwY3XzJGRESS2rbnT1Z4VlKGGyb4D0c5Nqey5? MV:yOFIxOThzMh?=
WiDr Mn7jSpVv[3Srb36gRZN{[Xl? MkX0NVBuVQ>? M2nrd|Fp M2ThSolvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? NWPsW4lWOjRzOUC0PFk>
H1299  NXHmO3pHTnWwY4Tpc44hSXO|YYm= NUDoXVVsOTCvTR?= NXW5eYE{PGh? NVrwN5l3cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? M{jFdFI1OTd|MkC4
H460 NWC3UJJSTnWwY4Tpc44hSXO|YYm= M4nwSVExdU1? NWPGR4Y1PGh? NX7pNotJcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? Ml;FNlQyPzN{MEi=
A549 MYjGeY5kfGmxbjDBd5NigQ>? MkLYNVBuVQ>? Mlz6OIg> M3vvfolvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGm{cnHkbYF1cW:w NFvHcGEzPDF2MkezOS=>
Hep3B M3rVcGFxd3C2b4Ppd{BCe3OjeR?= MVe1cW0> M2WxWFI1cA>? M4j1VoF1fGWwdXH0[ZMhXE6ILd8xJJBzd3SnY4Tpc44h[WejaX7zeEB{\XK3bTDzeIFzfmG2aX;uMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NInQd4wzPDB4Nk[5Ny=>
SMMC-7721 Mn;6RZBweHSxc3nzJGF{e2G7 MnGxOY1O NIDuU5czPGh? M1vOVYF1fGWwdXH0[ZMhXE6ILd8xJJBzd3SnY4Tpc44h[WejaX7zeEB{\XK3bTDzeIFzfmG2aX;uMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NHvhRpgzPDB4Nk[5Ny=>
HO8910 M17IT2Fxd3C2b4Ppd{BCe3OjeR?= MYWxNI1O Ml7tNVJp NGjMTYlmdmijbnPld{BDOTlvaX7keYNm\CCjcH;weI9{cQ>? Mle0NlM6QDN4MUC=
MCF7 M33MOGZ2dmO2aX;uJGF{e2G7 MXK1cW0> M4H2UFI1cA>? NEW2e29qdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= M2HlXVI{QTZ{NkK5
HONE-1  NF;QdFJHfW6ldHnvckBCe3OjeR?= NWjCWZdOPW2P MoXENYg> MnXRdoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u MXmyN|g6OjN3OB?=
HeLa MVXGeY5kfGmxbjDBd5NigQ>? NVPoV3k4OTCvTR?= M1zLOFJp Mlryd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> MmHWNlM5PjR5M{i=
HepG2 MUHGeY5kfGmxbjDBd5NigQ>? MlXyNVBuVQ>? NG\YbogzPGh? M2LvZYlvcGmkaYTzJJNqXEmJQWKtJIFv\CCKQmPTMYlv\HWlZXSgZZV1d3CqYXf5 MV2yN|gyPzB2MB?=
SH-SY5Y M4HH[2Z2dmO2aX;uJGF{e2G7 M{LzXVFuVQ>? NYPWe215OjSq M{XXUYlvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDUU2NR MV6yN|c1OzF2OB?=
SH-SY5Y NYTwd4l1SXCxcITvd4l{KEG|c3H5 MXG1cW0> NUH4TmlJOWh? NF\1UZFi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= M33GXFI{PjF7M{m1
PC12  MlXlSpVv[3Srb36gRZN{[Xl? M1;GdFExdU1? NXm2d5M1OjSq M3LpN5difGW{ MkP5xsBqdmirYnn0d{BkcHmvb4TyfZB{cW5vbHnr[UBxem:2ZXHzc41idCCjY4Tpeol1gS5? MkTHNlM3ODN7N{m=
OV2008 M3u2bGFxd3C2b4Ppd{BCe3OjeR?= Mnr4OY1O MWOyOIg> MoPtZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? NEnoeFczOzV7MkK4NS=>
A2780 MWPBdI9xfG:|aYOgRZN{[Xl? NXjyZpBtPW2P MV:yOIg> Mlv6Z49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? NVq0PYNXOjN3OUKyPFE>
Saos-2  NFnqNJpCeG:ydH;zbZMhSXO|YYm= M1X5SVFuVQ>? MVm5Oog> M1fXdYlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwZIXj[YQh[nliUFPY NG\LRWczOzV4M{G3NS=>
1321N1 NH[wcnNEgXSxdH;4bYNqfHliQYPzZZk> NX3pdGZxPW2P MUeyOIg> NUPNdWNmeHKxdHXjeJMh[2WubDDh[4FqdnO2IGDDUk1qdmS3Y3XkJJRwgGmlaYT5 MUWyN|UzPTJ4NR?=
SH-SY5Y NYj3OIZQS3m2b4TvfIlkcXS7IFHzd4F6 MkTPOY1O MYWyOIg> MUXpcoNz\WG|ZYOgVGNPKHSxeHnjbZR6 NEP5W2ozOzV{NUK2OS=>
HT-29  MXLGeY5kfGmxbjDBd5NigQ>? NW\xS2M6OW2P NHfTSXQ1QC97Nni= NXX4c5hqcW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> NXLtepVpOjN3MEiyO|I>
OR6 NF7CRYhHfW6ldHnvckBCe3OjeR?= MUKxNI1O NV3VcXN{PzKq M2TQfpN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? NWGzRmVzOjN|OUW4O|U>
Hela  M{TJUmZ2dmO2aX;uJGF{e2G7 Ml60OY1O NUnrRmpDOjSq M1;hbYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> M3HId|I{Ozl3Nke5
MCF-7  MmPYSpVv[3Srb36gRZN{[Xl? NF[1N4c2dU1? MkGzNlRp MVrpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 MYSyN|M6PTZ5OR?=
HUVECs NHH4emFHfW6ldHnvckBCe3OjeR?= NVjFeY9wO22P NUW1b2lTOjSq NYHSdVNv[myxY3vzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDy[ZN3\XKjdILvcEBjgSCrbnjpZol1cW6pIHH1eI9xcGGpeR?= NVi4ZWR4OjN|NUi5Nlg>
T24 M4facWZ2dmO2aX;uJGF{e2G7 NIPCUXcyOG2P MYGxbC=> M3X5c5Jm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS= MoPRNlM{PTRyOEC=
U251MG  NXn4c|BiTnWwY4Tpc44hSXO|YYm= NYnPUGU5O22P MUixbC=> MoTmd5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u NYLVZ4t4OjN|M{i2NVg>
GTL-16  NVXzNGFvSXCxcITvd4l{KEG|c3H5 MVW1cW0> NUXTc2NUOjSq MkLxdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjczDjc41x[XKnZDD0c{Bk\WyuczD0doVifGWmIIfpeIghVUWWIHnubIljcXSxcoO= Mo\ONlM{OTN2OUC=
T-47D NVjuZnVuTnWwY4Tpc44hSXO|YYm= MojSNVBuVQ>? MlXhNog> MmrZbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? MYeyN|MxODB{Nh?=
PaCa44 M37XZWFxd3C2b4Ppd{BCe3OjeR?= MUSyMlVuVQ>? MV2xbC=> M{nEPJJm\HWlZYRCpIdmdmmyaX6tcYVlcWG2ZXSgZZBweHSxc3nz NES1c3gzOzF{NEGxNi=>
MDA-MB231 M1\MPGZ2dmO2aX;uJGF{e2G7 NGKy[mM2dU1? M1jGdFFp M375fIlv[3KnYYPld{Bz\XO4ZYLheJJwdC2vZXTpZZRm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> M1fNeFI{ODh6OEWw
HeLa NIXDS45CeG:ydH;zbZMhSXO|YYm= M2fCbFExdU1? NFe5OpAzcA>? MXjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSvZX70JJdqfGhiUFXJ M{PjVVI{ODByMUO1
SK-HEP-1 M1z3NmFxd3C2b4Ppd{BCe3OjeR?= NVfvWlY6OTCvTR?= MX[xbC=> NFnhZnhxem:2ZXP0d{Bi\2GrboP0JIF2fG:yaHHnfUBidmRiaX7keYNmeyCjcH;weI9{cXNiaX6gZpVn[Wyrbj30doVifGWmIHPlcIx{ M2LtV|IzQDV6NkS5
HepG2 NWXzXINWSXCxcITvd4l{KEG|c3H5 MXOzcW0> NI\vNXo2cA>? MoXqdoVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> NF7ZZpozOjh|NkW5OS=>
MCF-7  MUHGeY5kfGmxbjDBd5NigQ>? M3fPTlJuVQ>? Ml;0NlRp NXzNTJlLcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> MlPCNlQ6PzB4N{[=
MDA-MB-231 MXXGeY5kfGmxbjDBd5NigQ>? NH\JWG8zdU1? MmfnNlRp NGjwPGVqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMg MlmyNlQ6PzB4N{[=
MCF-7  NF\lb|VHfW6ldHnvckBCe3OjeR?= MUCycW0> MlWxOFhp Mn7ZdJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRp M1XwW|I1QTdyNke2
MDA-MB-231 M{LwUWZ2dmO2aX;uJGF{e2G7 NGPjRoMzdU1? NGraT5c1QGh? MWPwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> MWeyOFk4ODZ5Nh?=
PANC-1  Mme2RZBweHSxc3nzJGF{e2G7 MWexcW0> MljzOFhp MoG5SG1UVw>? M1\tcoVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NEm0[WozPDh2MkG1PC=>
MDA-MB 231 MnHLRZBweHSxc3nzJGF{e2G7 M2DETlVuVQ>? NFzTZYYxNjWq NUL1eoZTdW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN? Mn3lNlQ5OzB5OEG=
Microglia  MWPBdI9xfG:|aYOgRZN{[Xl? M3v4e|VuVQ>? Mn;ZNlRp NI\4[lll\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> MX[yOFgyQDZyMR?=
A2780cp MWDBdI9xfG:|aYOgRZN{[Xl? NFGyeoIzNjWvTR?= MmDNNYg> M2S5WIRlUDKR MXvlcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo NVjTSHRxOjR6MUe5OFY>
HepG2 NEjy[WpHfW6ldHnvckBCe3OjeR?= NHfHTpA2dU1? MlrkOIg> M3\qOYlv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?= MXOyOFcyOzV6Nx?=
U2OS NEm5fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\CbolYOTCvTR?= NVvsbHpmOjSq NYrVRlNucW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhTG:6 NHrGfm0zPDZ|OUCxNy=>
HCT116 M4DZbWFxd3C2b4Ppd{BCe3OjeR?= NG[5bIY2dU1? NG\tUYYzPGh? MX7EUXNQ Monp[Y5p[W6lZYOgZZBq\2WwaX6tbY5lfWOnZDDj[YxtKGSnYYTo Mn3aNlQ3OjZ3MkK=
MCF-7  MVrBdI9xfG:|aYOgRZN{[Xl? M1jzUVAvOW2P NYDrOmtmPmh? M4PNfoVvcGGwY3XzJJNqenSrbn;sMYlv\HWlZXSgZZBweHSxc3nz NELJWHkzOjd3MUm4PS=>
PC-3  NIjPNnRCeG:ydH;zbZMhSXO|YYm= MmS2No1O M2jXUFJp MoTjbY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? MXWyNlc1PTV6MB?=
U251  NWrINnJFSXCxcITvd4l{KEG|c3H5 MoXDOY1O MlTWNlRp Mo\NbY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? MnvNNlI2Pzl5OEi=
HeLa  MnnERZBweHSxc3nzJGF{e2G7 NUfCXph{PW2P M33Ge|I1cA>? MWnpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= MWCyNlU1PTF{OB?=
A549 MmTNSpVv[3Srb36gRZN{[Xl? MoDWNE4ydU1? NEG0W|MzPGh? MkXNd5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MX6yNlQ3Pjl4MB?=
pDCs NGfOemNHfW6ldHnvckBCe3OjeR?= MV:xNI1O MmnUNE42cA>? MmnjxsBz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gTWZPNc7zIHL5JJN{Wk6DNEC= MofaNlI{QTZ3OUm=
BGC-823 M1rLbGZ2dmO2aX;uJGF{e2G7 M4HuU|VuVQ>? MXKybC=> NF3ET3JqdmirYnn0d{B1cGVicnH0[UBw\iCjdYTvdIhi\2mlIHPlcIx{ Ml:wNlI{OjJzNUK=
U937 MXXGeY5kfGmxbjDBd5NigQ>? M1;NbVJuVQ>? M4iyXVEzcA>? NYrsSmhz\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= NYPtSXVDOjJzNUWxOVA>
Marc-145 MXvGeY5kfGmxbjDBd5NigQ>? M{XSVlVuVQ>? M2fzeFEzNzJ2L{O2bC=> NVjtenpbemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u MnLQNlIyOTl7MEC=
HBx  NVTZT4dlSXCxcITvd4l{KEG|c3H5 NEThXFEyOG2P MWq0PIg> NV7pSYVnTE2VTx?= M{PFRolv[3KnYYPld{Bk\WyuIHTlZZRp NYnzdJJEOjJyMkCwO|g>
MCF-7 M2LyN2Z2dmO2aX;uJGF{e2G7 MnHjNVBuVQ>? NXj6VmhVPDiq MoPuZoxw[2u|IHH1eI9xcGGpeTDpcoR2[2WmIHL5JIJwenSnen;tbYI> MU[yNVk{OTl|Nx?=
RMPI8226  M4fndWZ2dmO2aX;uJGF{e2G7 NWrQdnJNPW2P NF;kOpoycA>? NFvIVZp{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w MU[yNVkyPTZ{MB?=
PC12/TetOn MUPGeY5kfGmxbjDBd5NigQ>? MXSwMlEwOW2P MXixPIg> MVLs[YFleyC2bzFOtU1{gW5qV2SpJIFk[3WvdXzheIlwdixidH;4bYNqfHluIHHu[EBwdGmpb33ldkBnd3KvYYTpc47DqA>? M3zSRVIyQTB4NkW5
HeLa  NV3JVmdJS3m2b4TvfIlkcXS7IFHzd4F6 MkLrNo1O MWCyOIg> MmLxbY5pcWKrdHXzJJRp\SCleYTveI95cWOrdImgc4Yhe2muaXLpcolvKHSxIFjlUIEh[2WubIOu NGrj[XUzOTh5NUO4OS=>
Jurkat M2fSRWZ2dmO2aX;uJGF{e2G7 Mn3jNVBuVQ>? MUCxbC=> NWHNPZNO\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MY[yNVg3PDB|Nx?=
K562 M4PZe2Z2dmO2aX;uJGF{e2G7 NFfuc|QyOG2P M1\ZNFFp MknP[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NVjpdZJZOjF6NkSwN|c>
Nara-H MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHWV242dU1? NW\XemFZPDiq NUXab3A4\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> MmrxNlE5ODVyM{O=
HUVECs M4CwXGZ2dmO2aX;uJGF{e2G7 NXvidW9qOTCvTR?= NHLOeYUxNjWq MWXk[YNz\WG|ZYOgeIhmKEGJRT3CV2FqdmS3Y3XkJIF2fG:yaHHnfUBt\X[n Mk\lNlE1Pjh3OUK=
HepG2 M1;zdWFxd3C2b4Ppd{BCe3OjeR?= M3u3PVJuVQ>? MlvzNYg> NUf5NXJW\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDDk[YF1cA>? NUDCS40zOjF2NUO2PVE>

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID